CD274 and in situ carcinoma: In HNSCC, when scoring PD-L1 expression, tumor-associated immune cells should be differentiated from chronic inflammation, and PD-L1–positive carcinoma in situ or dysplasia should be excluded when assessing invasive cancer (80).